London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
A timely update on where this Company is and is going I could not be more pleased with the progress, it looks like this will go places.
Why is this static today? Should be taking off like a jet from Northolt.
It's a slightly confusing update. They got approval from the FDA last month, and fast-tracked for approval in Europe, but now the first use case is in the UK. From previous updates you might have thought the US would be first? Anyway the big news is they are into manufacturing now, so the revenues from this excellent new product should start rolling in next year, from both markets.
Today's the day, surely? The sales team is strongly building global momentum. This is set to explode. Not a ramp... I feel genuinely inspired by this story.
Another step forward for this great little company.
I am in full agreement. The thing clearly holding it back is any ongoing funding worry. If the sales go well however that concern should evaporate in a puff of contracts. I invested in these several years ago at much higher levels but came back in for a lot more recently having decided to take a chance on sales bringing in sufficient income to prevent any future dilutive fund raise. So fingers crossed.
Strange newsflow. It's as if they read my comment a couple of days ago and decided to reply with a whole raft of use cases from the States ( : Surely they knew about this when the previous RNS went out - or did all these procedures happen this week? ( : Anyway, great news that Creo tech is suddenly addressing so many different patient conditions. Shows how quick adoption can happen. With trained eager physicians ready to go, and manufacturing in place, it feels like most of the hard work has been done now and it's time to reap the rewards and move forward with other products. Not quite certain yet, but it really looks like this is the start of a VERY positive step change in this branch of surgery, with Creo right at the heart of it.
From Creo Twitter
Following our EMEA and USA milestones, this week Speedboat UltraSlim was used for the first time in Latin America with Dr Michel Kahaleh, Dr Juan Alcivar and Dr Eduardo Albeniz performing #POEM & #FPOEM procedures at #IECED Hospital, Ecuador.
Firstly, to address any lingering doubt with regards to future funding requirements, on the current trajectory the evidence strongly suggests further funding would no longer be required to support future organic growth before reaching profitability. With a caveat, should the demand for Speedboat Ultraslim exceed current production capacity to such an extent to trigger a requirement for further investment in manufacturing capacity, or for growth by acquisition.
In either scenario, this would be backed up by a material increase in revenues from the current baseline.
This is now without doubt, a very exciting time for the company and its investors.
A few years ago, Baillie Gifford cited Creo as one of the most exciting and innovative companies they had come across in many years and they became a significant shareholder.
But due recently to the worst market conditions for AIM and small cap growth companies in the living memory of most, and due to being a forced seller because of fund redemptions, their stake in the company has been reduced to 1.995%, down from a previous holding of 7.30% in June last year.
In hindsight, I think BG were a little ahead of their time with Creo.
To quote a famous song from Bob Dylan: "The Times They Are A-Changin’"
As has been seen, Creo have got off to a very positive start ahead of the new year with first use cases of Speedboat Ultraslim in the USA and Europe and most recently, Latin America.
These cases provide a great platform for endorsement and I imagine that their phone lines are ringing hot and the management and salesforce teams are working a lot of overtime.
We anticipate a lot of news on progress in the new year and the update from NICE. Although we don't yet know what the outcome of that will be and Speedboat is already being used to great effect in some UK hospitals, we should be reminded of the recent statement from Creo's CEO in this regard:
"Using our technology, initial
health economic data has
demonstrated that the NHS
can save approximately
£5,000 per procedure"
Excerpt from a research note published by Edison on 14th December 2023 that concludes with:
"In November 2023, Speedboat UltraSlim received 510(k) clearance from the FDA for its Speedboat UltraSlim device, close on the heels of the accelerated clearance pathway in Europe (18 months earlier than anticipated). Management has indicated that the validation work and transfer to manufacturing has now been completed and launch activities should pick up pace in the coming weeks, with a full launch anticipated in early 2024 in Europe. We believe this will be swiftly followed by a launch in the US as well as in other geographies such as Asia-Pacific. We see the launch of the UltraSlim version as a key commercial win for Creo, supporting greater top-line traction for the core portfolio in FY24."
https://www.edisongroup.com/research/ultraslim-launch-kicking-off-fy24-momentum/33060/
Can anyone tell me what the MCap was when this raised significant capital at £1.80 without me having to look it up.
I can see the SP has gone up from the 20p Raise to 37p and we are at £132m value today so I’m guessing the last raise was based on about £60m ? But how does that relate to the earlier raise?
Has the value of the business gone up or down over the last three years? Thanks
Yes there was a raise at 20p putting the market cap at around £60m, following a steady decline from a high of around 230p. Main reasons for the decline were failure to get any traction with core sales of devices, not helped by Covid, a blow out with costs including an extraordinary increase in headcount to 350. In March the company pledged to reduce this to 250, something they said they could do because r & d had peaked. Other poor decisions included appointing a new director who promptly joined the remuneration committee which then awarded key directors massive bonuses. Imo a very poor decision. Since the March raise there are signs of a revival, early traction with sales, new fda approvals, a lot of hope of a deal with one or more of the robotic surgery leaders. I am guessing that the recent uplift in sp is on the back of some positive news in the arena but this not confirmed. Would be very interested if anyone has details of current headcount, even better details of cost reductions. I remain confident that the company will prevail because the technology remains cutting edge however I think there is a call for a management refresh. Back to basics, cut costs, narrow focus to sales of devices, maybe even jettison acquisitions which have sucked in cash and distracted from main objective.
There were raises at 75p and 125p as I recall, do not remember one at 180p.
Placing of c. £31 million followed by open offer :-
The Company is pleased to announce that, further to the announcement made on 12 August 2021 (RNS No: 5145I ) regarding the Fundraising (the "Launch Announcement"), it is proposing to raise up to approximately £5.07 million (before expenses) through an Open Offer pursuant to which Qualifying Shareholders will have an opportunity to subscribe for an aggregate of 2,775,896 Open Offer Shares at an Offer Price of 182.5 pence per Open Offer Share.
Nice rise today. Heading in 2025 for my 100p SP target.
2024 you mean
@Theorist
Thanks for the reply, appreciated,
This is certainly on my watch list, product side is certainly impressive. My only concern is the cash burn. They believe they can be cash flow positive in 2025 but a quick calculation of CAB at 30/6 indicates a burn of circa 20m in H1 with 26m remaining so if they spend same in H2 we would have about £6m left in Q1 24 so looks to me a further raise bolted on first quarter which could be why they are at the pitching event on the 11th Jan. you don’t bother with pitching events if you are fully funded. Not a bad thing but I would want to know what that looks like and indications they can make this viable.
Speedboat is VERY impressive for sure but MCap is also fairly racey IMO. I will attend the pitching event if I can get down to London. Add a few in the next placing if they can demonstrate stronger fiscal control.
Good luck with this one, a solid base they are building from for sure
Interesting article in Sunday Times magazine about robotic surgery. Creo are bang on the button for this and the normal laparoscopic techniques. The Da Vinci robots being described are made by Intuitive Surgical as referenced previously.